▶ 調査レポート

パーキンソン病治療薬の世界市場分析・規模・シェア・成長・動向・予測:薬剤クラス別(レボドパ併用剤、ドーパミン作動薬、MAO-B阻害剤、COMT阻害剤)、投与経路別(経口、経皮、皮下、経腸)、販売チャネル別(院内薬局、小売薬局、オンライン)

• 英文タイトル:Parkinson’s Disease Therapeutics Market (Drug Class - Levodopa Combination, Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors; Route of Administration - Oral, Transdermal, Subcutaneous, Intestinal Infusion; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Transparency Market Researchが調査・発行した産業分析レポートです。パーキンソン病治療薬の世界市場分析・規模・シェア・成長・動向・予測:薬剤クラス別(レボドパ併用剤、ドーパミン作動薬、MAO-B阻害剤、COMT阻害剤)、投与経路別(経口、経皮、皮下、経腸)、販売チャネル別(院内薬局、小売薬局、オンライン) / Parkinson’s Disease Therapeutics Market (Drug Class - Levodopa Combination, Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors; Route of Administration - Oral, Transdermal, Subcutaneous, Intestinal Infusion; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025 / TPM-B05162資料のイメージです。• レポートコード:TPM-B05162
• 出版社/出版日:Transparency Market Research / 2018年4月20日
• レポート形態:英文、PDF、211ページ
• 納品方法:Eメール
• 産業分類:Pharmaceutical
• 販売価格(消費税別)
  Single User¥614,270 (USD5,795)▷ お問い合わせ
  Multi User¥932,270 (USD8,795)▷ お問い合わせ
  Global Site License¥1,250,270 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、パーキンソン病治療薬の世界市場について調べ、パーキンソン病治療薬の世界規模、市場動向、市場環境、薬剤クラス別(レボドパ併用剤、ドーパミン作動薬、MAO-B阻害剤、COMT阻害剤)分析、投与経路別(経口、経皮、皮下、経腸)分析、販売チャネル別(院内薬局、小売薬局、オンライン)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。
・序文・調査範囲・調査手法
・エグゼクティブサマリー
・パーキンソン病治療薬の世界市場動向
・パーキンソン病治療薬の世界市場環境
・パーキンソン病治療薬の世界市場規模
・パーキンソン病治療薬の世界市場規模:薬剤クラス別(レボドパ併用剤、ドーパミン作動薬、MAO-B阻害剤、COMT阻害剤)
・パーキンソン病治療薬の世界市場規模:投与経路別(経口、経皮、皮下、経腸)
・パーキンソン病治療薬の世界市場規模:販売チャネル別(院内薬局、小売薬局、オンライン)
・パーキンソン病治療薬の世界市場:地域別市場規模・分析
・パーキンソン病治療薬の北米市場規模・予測
・パーキンソン病治療薬のアメリカ市場規模・予測
・パーキンソン病治療薬の中南米市場規模・予測
・パーキンソン病治療薬のヨーロッパ市場規模・予測
・パーキンソン病治療薬のアジア市場規模・予測
・パーキンソン病治療薬の日本市場規模・予測
・パーキンソン病治療薬の中国市場規模・予測
・パーキンソン病治療薬のインド市場規模・予測
・パーキンソン病治療薬の中東市場規模・予測
・パーキンソン病治療薬のアフリカ市場規模・予測
・競争状況・関連企業情報

Parkinson’s Disease Therapeutics Market – Overview

This report on Parkinson’s disease therapeutics market studies the current as well as future prospects of the market globally. Stakeholders of the market include companies and intermediaries engaged in the manufacturing, commercialization, providing therapeutic drugs for treatment of Parkinson’s disease, as well as new entrants planning to enter the market. The report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments considered in the scope of the study. The section also provides overall information and data analysis of the global Parkinson’s disease therapeutics market with respect to the leading market segments based on drug class, route of administration, distribution channel, and geography.

The global Parkinson’s disease therapeutics market is divided into four segments on the basis of drug class, route of administration, distribution channel, and geography. Based on drug class, the market has been further segmented into Levodopa combination, dopamine agonists, MAO-B Inhibitors, COMT Inhibitors, and others. In terms of route of administration, the market has been classified into oral, transdermal, subcutaneous, intestinal infusion, and others. The Parkinson’s disease therapeutics market has also been studied from the point of distribution channel, based on which the market has been bifurcated into hospital pharmacy, retail pharmacy, and online pharmacy.

Each of the market segments has been extensively analyzed based on market-related factors such as increasing incidence and prevalence of Parkinson’s disease. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ million for each segment have been provided for the period from 2015 to 2025. The report also provides the compound annual growth rate (CAGR) percentage for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.

The market overview section of the report explores the market dynamics such as drivers, restraints, opportunities, and pipeline drugs that currently have a strong impact on the Parkinson’s disease therapeutics market and is likely to influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors are expected to help market players take strategic decisions to strengthen their positions and enhance their shares in the global Parkinson’s disease therapeutics market.

Geographically, Parkinson’s disease therapeutics market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions have been provided for the period from 2015 to 2025, along with their respective CAGR for the forecast period from 2017 to 2025, considering 2016 as the base year. The report provides market size and forecast for the major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market growth and future opportunities has been provided in the market overview section. It also provides market attractiveness analysis and market share analysis of key players, thus presenting a thorough examination of the overall competitive scenario of the global Parkinson’s disease therapeutics market.

Major players operating in the global Parkinson’s disease therapeutics market are AbbVie Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., and UCB Inc, which exhibit the widest geographical outreach. Other prominent players operating in the global market include STADA Arzneimittel AG, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc., and Impax Laboratories Inc.

The global Parkinson’s disease therapeutics market is segmented as follows:

By Drug Class

Levodopa Combination
Dopamine Agonists
MAO-B Inhibitors
COMT Inhibitors
Others
By Route of Administration

Oral
Transdermal
Subcutaneous
Intestinal Infusion
Others
By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Geography

North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America (LATAM)
Brazil
Mexico
Rest of LATAM
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa

レポート目次

Chapter 1 Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2 Assumptions and Research Methodology

Chapter 3 Executive Summary: Global Parkinson’s Disease Therapeutics Market

Chapter 4 Market Overview
4.1. Introduction
4.2. Key Industry Developments

Chapter 5 Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities
5.4. Global Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, 2015–2025
5.5. Global Parkinson’s Disease Therapeutics Market Outlook
5.6. Global Prevalence of Parkinson’s Disease
5.7. Pipeline Analysis

Chapter 6 Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Key Findings
6.2. Introduction
6.3. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
6.3.1. Levodopa Combination
6.3.2. Dopamine Agonists
6.3.3. MAO-B Inhibitors
6.3.4. COMT Inhibitors
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Class

Chapter 7 Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Route of Administration
7.1. Key Findings
7.2. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
7.2.1. Oral
7.2.2. Transdermal
7.2.3. Subcutaneous
7.2.4. Intestinal Infusion
7.2.5. Others
7.3. Market Attractiveness Analysis, by Route of Administration
7.4. Key Trends

Chapter 8 Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2025
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy
8.3.3. Online Pharmacy
8.4. Market Attractiveness Analysis, by Distribution Channel

Chapter 9 Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Market Scenario
9.3. Market Value (US$ Mn) Forecast, by Region, 2017-2025
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Market Attractiveness Analysis, by Region

Chapter 10 North America Parkinson’s Disease Therapeutics Market Analysis and Forecast
10.1. Key Findings
10.2. Market Size (US$ Mn) Forecast, by Country, 2017-2025
10.2.1. U.S.
10.2.2. Canada
10.3. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
10.3.1. Levodopa Combination
10.3.2. Dopamine Agonists
10.3.3. MAO-B Inhibitors
10.3.4. COMT Inhibitors
10.3.5. Others
10.4. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
10.4.1. Oral
10.4.2. Transdermal
10.4.3. Subcutaneous
10.4.4. Intestinal Infusion
10.4.5. Other
10.5. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2025
10.5.1. Hospital Pharmacy
10.5.2. Retail Pharmacy
10.5.3. Online Pharmacy
10.6. Market Attractiveness Analysis
10.6.1. By Country
10.6.2. By Drug Class
10.6.3. By Route of Administration
10.6.4. By Distribution Channel

Chapter 11 Europe Parkinson’s Disease Therapeutics Market Analysis and Forecast
11.1. Key Findings
11.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
11.2.1. Germany
11.2.2. U.K.
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Rest of Europe
11.3. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
11.3.1. Levodopa Combination
11.3.2. Dopamine Agonists
11.3.3. MAO-B Inhibitors
11.3.4. COMT Inhibitors
11.3.5. Others
11.4. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
11.4.1. Oral
11.4.2. Transdermal
11.4.3. Subcutaneous
11.4.4. Intestinal Infusion
11.4.5. Others
11.5. Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2025
11.5.1. Hospital Pharmacy
11.5.2. Retail Pharmacy
11.5.3. Online Pharmacy
11.6. Market Attractiveness Analysis
11.6.1. By Country
11.6.2. By Drug Class
11.6.3. By Route of Administration
11.6.4. By Distribution Channel

Chapter 12 Asia Pacific Parkinson’s Disease Therapeutics Market Analysis and Forecast
12.1. Key Findings / Developments
12.2. Market Overview
12.3. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
12.3.1. China
12.3.2. India
12.3.3. Japan
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
12.4.1. Levodopa Combination
12.4.2. Dopamine Agonists
12.4.3. MAO-B Inhibitors
12.4.4. COMT Inhibitors
12.4.5. Others
12.5. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
12.5.1. Oral
12.5.2. Transdermal
12.5.3. Subcutaneous
12.5.4. Intestinal Infusion
12.5.5. Others
12.6. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2025
12.6.1. Hospital Pharmacy
12.6.2. Retail Pharmacy
12.6.3. Online Pharmacy
12.7. Market Attractiveness Analysis
12.7.1. By Country
12.7.2. By Drug Class
12.7.3. By Route of Administration
12.7.4. By Distribution Channel

Chapter 13 Latin America Parkinson’s Disease Therapeutics Market Analysis and Forecast
13.1. Key Findings / Developments
13.2. Market Overview
13.3. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
13.4.1. Levodopa Combination
13.4.2. Dopamine Agonists
13.4.3. MAO-B Inhibitors
13.4.4. COMT Inhibitors
13.4.5. Others
13.5. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
13.5.1. Oral
13.5.2. Transdermal
13.5.3. Subcutaneous
13.5.4. Intestinal Infusion
13.5.5. Others
13.6. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2025
13.6.1. Hospital Pharmacy
13.6.2. Retail Pharmacy
13.6.3. Online Pharmacy
13.7. Market Attractiveness Analysis
13.7.1. By Country/Sub-region
13.7.2. By Drug Class
13.7.3. By Route of Administration
13.7.4. By Distribution Channel

Chapter 14 Middle East & Africa Parkinson’s Disease Therapeutics Market Analysis and Forecast
14.1. Key Findings / Developments
14.2. Market Overview
14.3. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of Middle East & Africa
14.4. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
14.4.1. Levodopa Combination
14.4.2. Dopamine Agonists
14.4.3. MAO-B Inhibitors
14.4.4. COMT Inhibitors
14.4.5. Others
14.5. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
14.5.1. Oral
14.5.2. Transdermal
14.5.3. Subcutaneous
14.5.4. Intestinal Infusion
14.5.5. Others
14.6. Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2025
14.6.1. Hospital Pharmacy
14.6.2. Retail Pharmacy
14.6.3. Online Pharmacy
14.7. Market Attractiveness Analysis
14.7.1. By Country/Sub-region
14.7.2. By Drug Class
14.7.3. By Route of Administration
14.7.4. By Distribution Channel

Chapter 15 Competition Landscape
15.1. Global Parkinson’s Disease Therapeutics Market Share, by Company, 2016
15.2. Market Player – Competition Matrix (By Tier and Size of companies)
15.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
15.3.1. AbbVie, Inc.

Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Strategic Overview
15.3.2. UCB Inc.

Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Strategic Overview
15.3.3. Merck & Co., Inc.

Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.4. Valeant Pharmaceuticals International, Inc.

Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.5. Novartis AG

Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.6. Boehringer Ingelheim GmbH.

Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.7. GlaxoSmithKline plc.

Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.8. Teva Pharmaceutical Industries Ltd.

Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.9. STADA Arzneimittel AG.

Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.10. Impax Laboratories, Inc.

Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.11. F. Hoffmann-La Roche Ltd.

Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview

List of Tables

Table 01: Global Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 02: Global Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 03: Global Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 04: Global Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 05: North America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 06: North America Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 07: North America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 08: North America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 09: Europe Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 10: Europe Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 11: Europe Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 12: Europe Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 13: Asia Pacific Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 14: Asia Pacific Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 15: Asia Pacific Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 16: Asia Pacific Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 17: Latin America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 18: Latin America Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 19: Latin America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 20: Latin America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 21: Middle East & Africa Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 22: Middle East & Africa Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 23: Middle East & Africa Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 24: Middle East & Africa Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025